(Bloomberg) --Sanofi will focus on supplying Covid-19 booster shots and fine-tuning its messenger RNA platform for the next pandemic after delays placed the drugmaker at least a year behind rivals in developing vaccines.
That means halting the development of the company’s experimental messenger RNA shot, which would be redundant by the time it becomes available next year, according to Thomas Triomphe, executive vice president of Sanofi’s vaccines unit.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.